Navigation Links
Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy
Date:11/15/2007

HIV tropism status needed to initiate therapy with Pfizer's recently

approved Selzentry(TM) (Maraviroc), CCR5 antagonist

MALIBU, Calif., Nov. 15 /PRNewswire/ -- Pathway Diagnostics announces that the U.S. Patent & Trademark Office (USPTO) has issued U.S. Patent number 7,294,458 (the '458 patent) entitled "Analysis of HIV-1 Co-receptor Use in the Clinical Care of HIV-1-Infected Patients." Pathway Diagnostics has licensed the '458 patent (with rights to sub-license) from Health Research Incorporated (HRI), Rensselaer, NY for use in the fields of laboratory diagnosis and monitoring. The '458 patent discloses and claims diagnostic methods for monitoring CCR5 and CXCR4 co-receptor use in the treatment of human immunodeficiency virus (HIV) infection. The '458 patent also claims monitoring CXCR4-specific strain suppression in HIV-positive individuals undergoing highly active anti-retroviral therapy (HAART). Pathway has also obtained licensing rights from HRI for related patent applications, that together with the '458 patent, form the technical foundation of Pathway's SensiTrop HIV tropism assay.

"The patented technology underlying Pathway's SensiTrop assay is a significant innovation that enables HIV treating physicians to select the appropriate treatment for patients using a proprietary molecular assay that is fast and affordable. Pathway's partners have recognized the strength of Pathway's patent portfolio and the importance of these patents when testing CCR5 and CXCR4 co-receptor use for HIV therapy," stated Walter Narajowski, CEO of Pathway Diagnostics.

About HIV Co-receptor tropism and the SensiTrop(TM) assay

The ability of the HIV virus to infect different cell types utilizing different cell surface receptors is referred to as HIV co-receptor tropism. One type of HIV that utilizes the CCR5 co-receptor has been shown to be blocked by CCR5 antagonist drugs such as Selzentry. A different type of HIV that utilizes the CXCR4 co-receptor is not blocked by CCR5 antagonists. Therefore, determining the tropism status of HIV-infected patients has been indicated by the FDA before initiating CCR5 antagonist therapy.

Pathway's SensiTrop(TM) assay is a proprietary application of molecular hybridization based on heteroduplex tracking technology developed by Dr. Barbara Weiser and Dr. Harold Burger's laboratory at the Wadsworth Center, New York State Department of Health, Albany NY. Heteroduplex tracking technology interrogates the complete HIV V3 loop, detecting sequence differences that determine whether the patient's HIV utilizes either the CXCR4 or CCR5 co-receptor. SensiTrop, like other molecular based assays, is highly sensitive and rapid to perform.

About Pathway Diagnostics

Pathway Diagnostics Corporation focuses on the development, validation and commercialization of novel, proprietary biomarker assays across multiple disease areas that address unmet medical needs and improve patient care. The company combines assay development expertise with a broad range of advanced technology platforms, a fully licensed CLIA laboratory, and a growing portfolio of patent-protected biomarkers for pharmaceutical companies to use in drug development and for commercial reference laboratories and in vitro diagnostic manufacturers to license for use in patient testing. Pathway effectively bridges the gap between biomarker research and biomarker commercialization, as well as ensures a regulatory-compliant environment for laboratory testing for preclinical and clinical drug development programs.


'/>"/>
SOURCE Pathway Diagnostics
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
5. Strategic Diagnostics Updates Roth Conference Presentation Time
6. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
9. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
10. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
11. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies (APMT), ... Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd will ... “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment industries. ...
(Date:3/22/2017)... 2017 Good Start Genetics, a leading family ... 130 million covered lives mark through its most recent ... Texas . With newly signed contracts nationally and ... strong payor acceptance based on the quality of its ... counseling, its industry-leading customer care and support and its ...
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT announced ... "Company" or "Propellon"), a start-up created by FACIT ... therapeutics. FACIT,s investment, combined with non-dilutive capital, achieves ... The seed funding enables Propellon to accelerate the ... Company for financing and/or entering a strategic partnership ...
Breaking Biology Technology:
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that it ... insights to support its reporting, help direct future campaigns, and share ... charity will be using Brandwatch Analytics social listening and analytics technology ... the topics and issues that are a priority for its supporters. ... "Until recently we,ve ...
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
Breaking Biology News(10 mins):